Novartis’s $925M Anthos Acquisition Brings Back Cardio Drug That Stops Blood Clots
The Anthos Therapeutics acquisition represents a homecoming for its drug abelacimab, which originated in Novartis’s labs. The antibody offers the potential to prevent blood clots without the bleeding risks associated with currently available anticoagulants.
